Press release from Companies
Publicerat: 2022-11-10 12:33:59
Oslo, Norway, November 10, 2022 – November 14, 2022, is the last day of trading in warrants of series TO 1, which were issued in connection with Genetic Analysis AS’s ("GA" or the "Company") IPO of units in September/October 2021. The exercise period runs until November 16, 2022. Holders of warrants of series TO 1 are entitled to subscribe for one (1) new share in GA at a price of NOK 9.30 per share. The Company's share price is currently substantially lower than the subscription price and thus something that warrant holders should be aware of when considering possible subscription of shares.
General terms and conditions and information concerning the warrants of series TO 1: Advisors and issuing agent: For more information about warrants of series TO 1, please contact: For more information about GA, please contact: This is a translation of the Swedish original. If there is any inconsistency between the English and Swedish versions, the Swedish version shall prevail. About Genetic Analysis:
Sedermera Corporate Finance AB is the Swedish financial advisor to GA in connection with the exercise of warrants of series TO 1. The law firm Wiersholm AS is acting as legal advisor and DNB Bank ASA is acting as issuing agent. Shark Communication AB assists the Company with advice regarding communication.
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com
Website: www.genetic-analysis.com
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com